XIAMEN SPACEGEN Co., Ltd. (abbreviated as "SPACEGEN") is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs providing high-quality and accessible molecular diagnostic products and services, covering the whole-cycle of cancer management , including early screening, disease diagnosis, individualized medication guidance and continuous curative effect monitoring.

SPACEGEN owns 3,500 square meters of international standard GMP workshop and 2,000 square meters of research and development/quality control laboratory. SPACEGEN has a perfect quality management system, and has passed the TUV ISO 13485 medical device quality management system certification. SPACEGEN has wholly-owned subsidiaries Xiamen SpaceSeq MedLab Co., Ltd. and Suzhou SpaceSeq MedLab Co., Ltd. ,are equipped with four core technology platforms including high-throughput sequencing, fluorescent quantitative PCR, digital PCR and nucleic acidmass spectrometry, and have the laboratory qualifications for tumor molecular detection, pathogenic infection detection and drug metabolism detection. The laboratories have passed the NCCL/CAP/EMQN domestic and foreign room quality evaluation with full scores for consecutive years. The operation of the quality management system has obtained the authoritative certification from CAP of the United States.

SPACEGEN has independent patented RingCap technology, which is a targeted sequencing library preparation technology based on multiplex PCR. The library construction only needs two steps and can be completed in 3.5 hours.